Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12165436 | 0.84 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL1699450 | 0.84 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL28554942 | 0.84 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3OPRM1CHRM2 | |
| SCHEMBL13352355 | 0.83 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| Hydrochloric Acid SCHEMBL3925422 | 0.83 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL2639282 | 0.83 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL12278694 | 0.83 | TAAR1 (0.39) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL10613798 | 0.83 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL27414733 | 0.82 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3OPRM1CHRM2 | |
| SCHEMBL5349569 | 0.82 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3OPRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612210-B2 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2009-11-03 | — | — | US | disclosed |
| CN-101321741-A | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH CORP (US) | 2008-12-10 | — | — | CN | disclosed |
| EP-1957470-A1 | PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS | Wyeth (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007067501-A1 | PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS | WYETH (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2002046140-A1 | NOVEL CRYSTALLINE POLYMORPHIC FORMS OF VENLAFAXINE HYDROCHLORIDE AND A PROCESS FOR THEIR PREPARATION | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-06-13 | — | — | WO | disclosed |
| US-4761501-A | INTERMEDIATES FOR ANTIDEPRESSANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0112669-B1 | PHENETHYLAMINE DERIVATIVES AND INTERMEDIATES THEREFOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4611078-A | ANTIDEPRESSANT INTERMEDIATES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| US-4535186-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS; VENLAFAXINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0112669-A2 | Phenethylamine derivatives and intermediates therefor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | MAP2K4, MAP2K1, MAP2K6 | SLC6A2 3642/4885SLC6A4 3291/4885SLC6A3 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.